U.S. FDA approves AstraZeneca’s lung cancer drugs By Reuters


© Reuters. FILE PHOTO: AstraZeneca’s cancer medicine Imfinzi is seen in this undated handout image provided to Reuters, June 30, 2022. AstraZeneca/Handout via REUTERS

(Reuters) – Drugmaker AstraZeneca (NASDAQ:) said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA) when used along with chemotherapy for treatment of adults with stage IV non-small cell lung cancer.

Be the first to comment

Leave a Reply

Your email address will not be published.


*